source
- Tarsus to acquire Alkeus for $450 million, adding phase-3 retinal drug and oral Stargardt candidateTarsus Pharmaceuticals announced it will buy Alkeus Pharmaceuticals in a transaction valued at $450 million. The deal consists of $270 million in cash and $180 million of Tarsus common stock, givi…
- Braveheart charges past expectations with $382.5M IPO to fund cardio drug from HengruiBraveheart Bio has overcome its own IPO expectations, rallying $382.5 million in an upsized listing to fund its cardiovascular ambitions.Fierce Biotech · 22h ago↗ source